Archon Partners LLC Takes $5.12 Million Position in Illumina, Inc. $ILMN

Archon Partners LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 39,000 shares of the life sciences company’s stock, valued at approximately $5,115,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Bamco Inc. NY raised its position in shares of Illumina by 5.5% during the 4th quarter. Bamco Inc. NY now owns 219,566 shares of the life sciences company’s stock valued at $28,798,000 after buying an additional 11,472 shares in the last quarter. Guggenheim Capital LLC grew its holdings in shares of Illumina by 5.1% during the 4th quarter. Guggenheim Capital LLC now owns 35,745 shares of the life sciences company’s stock valued at $4,688,000 after purchasing an additional 1,743 shares during the last quarter. Caisse de depot et placement du Quebec grew its holdings in shares of Illumina by 121.9% during the 4th quarter. Caisse de depot et placement du Quebec now owns 338,251 shares of the life sciences company’s stock valued at $44,365,000 after purchasing an additional 185,810 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Illumina by 30.3% during the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after purchasing an additional 1,028,099 shares during the last quarter. Finally, Braidwell LP bought a new position in shares of Illumina during the 4th quarter valued at $35,370,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

ILMN has been the topic of several recent research reports. JPMorgan Chase & Co. raised shares of Illumina from a “neutral” rating to an “overweight” rating and increased their target price for the company from $125.00 to $185.00 in a report on Wednesday, June 10th. Royal Bank Of Canada initiated coverage on shares of Illumina in a report on Thursday, May 14th. They set an “outperform” rating and a $170.00 target price on the stock. Evercore reaffirmed an “outperform” rating on shares of Illumina in a report on Friday, May 1st. Wall Street Zen lowered shares of Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Guggenheim increased their target price on shares of Illumina from $170.00 to $180.00 and gave the company a “buy” rating in a report on Monday, June 1st. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $142.13.

Illumina Price Performance

Shares of Illumina stock opened at $159.09 on Thursday. The firm has a market cap of $24.07 billion, a PE ratio of 28.93, a price-to-earnings-growth ratio of 3.08 and a beta of 1.50. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $177.22. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The company’s fifty day simple moving average is $143.81 and its two-hundred day simple moving average is $135.76.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company’s revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts expect that Illumina, Inc. will post 5.21 EPS for the current year.

Insiders Place Their Bets

In other Illumina news, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the sale, the senior vice president owned 21,259 shares of the company’s stock, valued at $3,456,500.81. This trade represents a 3.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the completion of the sale, the director directly owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. This trade represents a 7.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 1,003,154 shares of company stock worth $155,600,208. 2.90% of the stock is currently owned by insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.